Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

M. Kadokura



Author of

  • +

    P1.03 - Chemotherapy/Targeted Therapy (ID 689)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Chemotherapy/Targeted Therapy
    • Presentations: 1
    • +

      P1.03-031 - Adherence and Feasibility of 2 Treatment Schedules of S-1 as Adjuvant Chemotherapy in Completely Resected Lung Cancer (ID 8829)

      09:30 - 09:30  |  Author(s): M. Kadokura

      • Abstract
      • Slides

      Background:
      S-1 is one of the key-drugs as chemotherapy for the non-small cell lung cancer (NSCLC). We conducted a multicenter randomized study of adjuvant S-1 administration schedules for surgically treated pathological stage IB-IIIA NSCLC patients.

      Method:
      Patients receiving curative surgical resection were centrally randomized to arm A (4 weeks of oral S-1 and a 2-week rest over 12 months) or arm B (2 weeks of S-1 and a 1-week rest over 12 months). The primary endpoints were total days of administration, and the secondary endpoints were relative total administration dose (relative dose intensity), toxicity, and 3-year disease-free survival. Total days of administration were evaluated according to the cumulative rates of total S-1 administration days within 224 days, at the end of 12 months. Relative dose intensity was defined as (the actual total dose administered divided by the planned total administered dose) × 100.

      Result:
      From April 2005 to January 2012, 80 patients were enrolled, of whom 78 patients were eligible and assessable. The cumulative rates of total S-1 administration days at the end of 12 months, were 81.3% for arm A (38 cases) and 60.2% for arm B patients (40 cases, p = 0.04). The relative dose intensity was 77.2% for arm A and 58.4% for arm B (p = 0.01). Drug-related grade 3 adverse events were recorded for 11% of arm A and 5% of arm B (p = 0.43). The 3-year disease-free survival rate was 79.0% for arm A and 79.3% for arm B (p = 0.94). Toxicity showed no significant difference among the shorter schedule and the conventional schedule, except for grade 1-3 elevation of bilirubin.

      Conclusion:
      The superiority of feasibility of the shorter schedule was not recognized in the present study. The conventional schedule showed higher cumulative rates of total S-1 administration days at the end of 12 months (p = 0.04) and relative dose intensity of S-1 (p = 0.01).

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.16 - Surgery (ID 732)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Surgery
    • Presentations: 1
    • +

      P3.16-008 - Thymidine Phosphorylase Influences Clinical Outcome Following Surgery in Patients with Stage I and II Non-Small Cell Lung Cancer (ID 9665)

      09:30 - 09:30  |  Author(s): M. Kadokura

      • Abstract

      Background:
      Expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), and orotate phosphoribosyltransferase (OPRT) may predict the clinical efficacy of 5-fluorouracil (5-FU) -based chemotherapy in patients with cancer. We investigated the differences in mRNA expression levels of these enzymes in non-small-cell lung cancer (NSCLC) and evaluated them as prognostic factors for NSCLC treated by surgical resection.

      Method:
      Intratumoral mRNA levels of TS, DPD, OPRT, and TP were quantified in 71 patients following a complete resection in pathological stage I and II NSCLC (adenocarcinoma or squamous cell carcinoma) using the Danenberg tumor profile (DTP) method.

      Result:
      TP was the only significant prognostic factor for overall survival (OS) following complete resection of stage I and II NSCLC. Median values of TP mRNA expression significantly differed between the high and low mRNA expression groups for OS. OS at 5 years was significantly better in the low TP mRNA expression group than the high TP mRNA expression group (82.5% vs. 63.6%, p < 0.001). The Cox’s proportional hazard model indicated that the pathological stage, sex, and TP expression were independent prognostic factors for OS. Univariate analysis for disease free survival (DFS) indicated that the pathological stage was the only prognostic factor for DFS. However, DFS at 5 years tended to be better in low TP mRNA expression group than in high TP mRNA expression group (88.9% vs. 67.3%, p=0.083).

      Conclusion:
      TP mRNA expression presents an independent prognostic factor for OS in patients with stage I and II NSCLC following complete resection.